257 related articles for article (PubMed ID: 22156495)
1. B cell-derived IL-10 does not regulate spontaneous systemic autoimmunity in MRL.Fas(lpr) mice.
Teichmann LL; Kashgarian M; Weaver CT; Roers A; Müller W; Shlomchik MJ
J Immunol; 2012 Jan; 188(2):678-85. PubMed ID: 22156495
[TBL] [Abstract][Full Text] [Related]
2. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.
Rankin AL; Guay H; Herber D; Bertino SA; Duzanski TA; Carrier Y; Keegan S; Senices M; Stedman N; Ryan M; Bloom L; Medley Q; Collins M; Nickerson-Nutter C; Craft J; Young D; Dunussi-Joannopoulos K
J Immunol; 2012 Feb; 188(4):1656-67. PubMed ID: 22231702
[TBL] [Abstract][Full Text] [Related]
3. IL-10 regulates murine lupus.
Yin Z; Bahtiyar G; Zhang N; Liu L; Zhu P; Robert ME; McNiff J; Madaio MP; Craft J
J Immunol; 2002 Aug; 169(4):2148-55. PubMed ID: 12165544
[TBL] [Abstract][Full Text] [Related]
4. Regulatory B cells in autoimmune diseases: how do they work?
Lemoine S; Morva A; Youinou P; Jamin C
Ann N Y Acad Sci; 2009 Sep; 1173():260-7. PubMed ID: 19758160
[TBL] [Abstract][Full Text] [Related]
5. The Unknown Aspect of BAFF: Inducing IL-35 Production by a CD5
Zhang Y; Li J; Zhou N; Zhang Y; Wu M; Xu J; Shen C; An X; Shen G; Yang M; Zhang C; Tao J
J Invest Dermatol; 2017 Dec; 137(12):2532-2543. PubMed ID: 28844943
[TBL] [Abstract][Full Text] [Related]
6. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice.
Lucas JA; Menke J; Rabacal WA; Schoen FJ; Sharpe AH; Kelley VR
J Immunol; 2008 Aug; 181(4):2513-21. PubMed ID: 18684942
[TBL] [Abstract][Full Text] [Related]
7. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
Cai Z; Wong CK; Dong J; Chu M; Jiao D; Kam NW; Lam CW; Tam LS
Clin Exp Immunol; 2015 Aug; 181(2):253-66. PubMed ID: 25845911
[TBL] [Abstract][Full Text] [Related]
8. FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease.
Yajima K; Nakamura A; Sugahara A; Takai T
Eur J Immunol; 2003 Apr; 33(4):1020-9. PubMed ID: 12672068
[TBL] [Abstract][Full Text] [Related]
9. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice.
Takahashi K; Kozono Y; Waldschmidt TJ; Berthiaume D; Quigg RJ; Baron A; Holers VM
J Immunol; 1997 Aug; 159(3):1557-69. PubMed ID: 9233655
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid factors in health and disease: structure, function, induction and regulation.
Haberman AM; William J; Euler C; Shlomchik MJ
Curr Dir Autoimmun; 2003; 6():169-95. PubMed ID: 12408052
[No Abstract] [Full Text] [Related]
11. Regulation of T cell-dependent autoantibody production by a gammadelta T cell line derived from lupus-prone mice.
Fujii T; Okada M; Craft J
Cell Immunol; 2002; 217(1-2):23-35. PubMed ID: 12425998
[TBL] [Abstract][Full Text] [Related]
12. Exacerbated autoimmunity in the absence of TLR9 in MRL.Fas(lpr) mice depends on Ifnar1.
Nickerson KM; Cullen JL; Kashgarian M; Shlomchik MJ
J Immunol; 2013 Apr; 190(8):3889-94. PubMed ID: 23467932
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
14. Terminal deoxynucleotidyl transferase deficiency decreases autoimmune disease in MRL-Fas(lpr) mice.
Feeney AJ; Lawson BR; Kono DH; Theofilopoulos AN
J Immunol; 2001 Sep; 167(6):3486-93. PubMed ID: 11544342
[TBL] [Abstract][Full Text] [Related]
15. Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus.
Lartigue A; Colliou N; Calbo S; François A; Jacquot S; Arnoult C; Tron F; Gilbert D; Musette P
J Immunol; 2009 Nov; 183(10):6207-16. PubMed ID: 19841185
[TBL] [Abstract][Full Text] [Related]
16. T cell reactivity to MHC class II-bound self peptides in systemic lupus erythematosus-prone MRL/lpr mice.
Suh CH; Freed JH; Cohen PL
J Immunol; 2003 Feb; 170(4):2229-35. PubMed ID: 12574397
[TBL] [Abstract][Full Text] [Related]
17. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice.
Takahashi S; Fossati L; Iwamoto M; Merino R; Motta R; Kobayakawa T; Izui S
J Clin Invest; 1996 Apr; 97(7):1597-604. PubMed ID: 8601623
[TBL] [Abstract][Full Text] [Related]
18. Cd72(c) is a modifier gene that regulates Fas(lpr)-induced autoimmune disease.
Xu M; Hou R; Sato-Hayashizaki A; Man R; Zhu C; Wakabayashi C; Hirose S; Adachi T; Tsubata T
J Immunol; 2013 Jun; 190(11):5436-45. PubMed ID: 23616572
[TBL] [Abstract][Full Text] [Related]
19. Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-lpr/lpr mouse model of systemic lupus erythematosus.
Gu L; Weinreb A; Wang XP; Zack DJ; Qiao JH; Weisbart R; Lusis AJ
J Immunol; 1998 Dec; 161(12):6999-7006. PubMed ID: 9862736
[TBL] [Abstract][Full Text] [Related]
20. Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling.
Rizzello C; Cancila V; Sangaletti S; Botti L; Ratti C; Milani M; Dugo M; Bertoni F; Tripodo C; Chiodoni C; Colombo MP
Mol Cancer; 2022 Dec; 21(1):215. PubMed ID: 36503430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
